Category: biologics

The invention relates to protecting against Salmonella-type pathogens and more particularly, compositions and methods for immunizing against infection by typhoidal and non-typhoidal Salmonella serovars.

Category(s):

The invention consists of new bi-functional protein inhibitors (“BPIs”) for treatment and diagnostics of autoimmune diseases such as MS and experimental autoimmune encephalomyelitis.  The novel BPIs are capable of modulating the immune response towards a TH2 response.

Category(s):
Subcategory(s):

Immuno-oncology represents the new wave of personalized medicine. Scientists at the University of Kansas have developed an innovative approach to activate intracellular signaling pathways that enhance T cell activation, expansion, and differentiation.

Category(s):
Subcategory(s):
Hearing loss, tinnitus, and vertigo result from the damage of mechanosensory hair cells (HCs) located in sensory epithelium of the cochlea and vestibular organs of the inner ear. HCs do not regenerate. Currently, hearing aids and cochlear implants are the only treatments to address hearing loss, and both options provide mild relief. The challenge in developing new therapies and screening ototoxic agents is that the cochlear and vestibular sensory epithelium are isolated deep in the inner ear. Invasive measures are required to access the sensory epithelium. KU researchers have endeavored to create both cochlear and vestibular sensory epithelium outside of the body. They are developing a model platform where the cochlear and vestibular sensory epithelium can be grown outside of the body for testing and developing new diagnostics, screening ototoxic agents, and evaluating new therapies. No such model currently exists. Thus, this technology has the potential to take a leap forward in the advancement of medicine for hearing disorders.
Subcategory(s):

Small molecule adjuvants that act as vaccine adjuvants by specifically binding to Toll-Like Receptor-8 (TLR8).

Category(s):
Subcategory(s):

The invention provides novel compounds (adjuvants) that can be used as agonists for Toll-Like Receptor 7 (TLR7).  By specifically targeting TLR7, these adjuvants elicit a type 1 interferon response which is essential in the development of antiviral responses.

Category(s):
Subcategory(s):

Events
KU Today